Atazanavir Metabolism According to CYP3A5 Status: An In Vitro-In Vivo Assessment-Reference-Cited by-同舟云学术

Atazanavir Metabolism According to CYP3A5 Status: An In Vitro-In Vivo Assessment

Published:2010-12-09 Issue:3 Volume:39 Page:522-527
ISSN:0090-9556
Container-title:Drug Metabolism and Disposition
language:en
Short-container-title:Drug Metab Dispos

Author:

Wempe Michael F.,Anderson Peter L.

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmaceutical Science,Pharmacology

Reference10 articles.

1. Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors

2. Atazanavir

3. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir

4. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes;Obach;Drug Metab Dispos,1999

5. ATAZANAVIR: EFFECTS ON P-GLYCOPROTEIN TRANSPORT AND CYP3A METABOLISM IN VITRO

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification, Separation and Characterization of Acidic and Oxide Degradation of Atazanavir Sulphate Under ICH-Recommended Stress Conditions by HPTLC with MS/ TOF;International Journal of Pharmaceutical Investigation;2024-07-01

2. Synthetic and Clinical Perspectives of Evotaz: An Overview;Mini-Reviews in Medicinal Chemistry;2024-03

3. How to use COVID-19 antiviral drugs in patients with chronic kidney disease;Frontiers in Pharmacology;2023-02-09

4. Development and Validation of Atazanavir and Ritonavir Determination in Human Plasma by HPLC-MS Method;Drug development & registration;2020-02-26

5. HIV-1 integrase tetramers are the antiviral target of pyridine-based allosteric integrase inhibitors;eLife;2019-05-23